RxDoctor Payments Data

Prabhakaran Gopalakrishnan, MD

Cardiovascular Disease · Canton, OHNPI 1992732663

Payments from drug & device makers

$122,793in general payments, 2019–2025

Across 70 payments — averaging $1754.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$82K
  • Amgen$23K
  • Ionis Pharmaceuticals, Inc.$10K
  • Pfizer$6K
  • Abbott$1K
  • E.r. Squibb & Sons, L.L.C.$100
  • plus $353 from 10 others

What the payments were for

  • Consulting fees$4,28855%
  • Travel & lodging$2,40031%
  • Food & beverage$1,08014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,793 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$175,970
Medicare patients
1,132
Services billed
2,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$263,117
JardianceEmpagliflozin150$133,853
EntrestoSacubitril/Valsartan88$96,020
XareltoRivaroxaban38$42,973
Repatha SureclickEvolocumab43$32,985
Metoprolol Succinate607$7,932
Bumetanide95$5,086
Dofetilide28$4,814
Ranolazine ErRanolazine63$4,255
Potassium Chloride248$3,175
Isosorbide Mononitrate ErIsosorbide Mononitrate341$2,995
Amiodarone Hcl48$2,808
Atorvastatin Calcium359$2,536
Losartan Potassium331$2,472
Rosuvastatin Calcium182$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,939$263,117256 claims
Boehringer IngelheimJardiance$33$133,853150 claims
NovartisEntresto$82,244$96,02088 claims
Johnson & JohnsonXarelto$16$42,97338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →